1. Home
  2. FLNT vs CRDF Comparison

FLNT vs CRDF Comparison

Compare FLNT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluent Inc.

FLNT

Fluent Inc.

HOLD

Current Price

$4.20

Market Cap

106.1M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.89

Market Cap

86.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLNT
CRDF
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.1M
86.8M
IPO Year
2009
2012

Fundamental Metrics

Financial Performance
Metric
FLNT
CRDF
Price
$4.20
$0.89
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$3.50
$9.63
AVG Volume (30 Days)
27.1K
799.1K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
41.67
27.37
EPS
N/A
N/A
Revenue
$208,764,000.00
$365,993.00
Revenue This Year
$5.89
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$1.70
$0.76
52 Week High
$4.49
$3.31

Technical Indicators

Market Signals
Indicator
FLNT
CRDF
Relative Strength Index (RSI) 61.55 41.71
Support Level $2.95 $0.76
Resistance Level $4.49 $1.13
Average True Range (ATR) 0.26 0.07
MACD 0.01 0.01
Stochastic Oscillator 65.42 17.72

Price Performance

Historical Comparison
FLNT
CRDF

About FLNT Fluent Inc.

Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: